Booth Bruce sold $34.8M of KYMR (indirect holdings)
Booth Bruce sold 285,684 indirectly-held shares of Kymera Therapeutics, Inc. (KYMR) at an average of $121.86 ($119.71–$129.61, $34.81M total) across 22 trades on 2026-06-25 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
A director sold 285,684 shares (weighted avg ~$121.86) for ~$34.81M, with holdings after the transaction at 529,718 shares; the sale was executed under a pre-arranged Rule 10b5-1 plan.
Market read
Traders may reassess near-term sentiment around KYMR due to the size of the sale, but the 10b5-1 structure suggests limited informational content.
What to watch
Indirect holdings and multiple small lots across 22 trades can make the sale look more dramatic than the underlying intent; also consider whether other insiders filed concurrent transactions.
Background
The article is an SEC Form 4 insider transaction disclosure for Kymera Therapeutics, Inc. (KYMR).
Ticker impact
Kymera Therapeutics director Booth Bruce sold $34.8M of KYMR shares via a 10b5-1 plan on 2026-06-25 at $119.71–$129.61.
Likely limited/short-lived impact; watch for any follow-through selling or unusual volume around the filing date.
The filing is primary-source (SEC Form 4) and transaction size is material, but the presence of a pre-arranged 10b5-1 plan reduces the signal of new information.
Market effects
Minimal sector read-through; this is company-specific insider liquidity rather than a sector-wide catalyst.
None indicated.
None indicated.
Counterpoint
Because it’s a 10b5-1 plan, the sale may be routine; traders may fade any immediate negative reaction and focus on upcoming fundamental catalysts instead.
Key entities
- issuerKymera Therapeutics, Inc.
Subject of the Form 4 insider sale; director Booth Bruce sold shares under a 10b5-1 plan.
- insiderBooth Bruce
Director who executed the open-market sale of KYMR shares.
